These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32246966)

  • 1. COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution.
    Kansal NK
    J Am Acad Dermatol; 2020 Jun; 82(6):e213. PubMed ID: 32246966
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution".
    Lebwohl M; Rivera-Oyola R; Murrell DF
    J Am Acad Dermatol; 2020 Jun; 82(6):e215. PubMed ID: 32283232
    [No Abstract]   [Full Text] [Related]  

  • 3. Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days.
    Coletto LA; Favalli EG; Caporali R
    Dermatol Ther; 2020 Jul; 33(4):e13415. PubMed ID: 32291828
    [No Abstract]   [Full Text] [Related]  

  • 4. Biologic therapy for psoriasis during the covid-19 outbreak is not a choice.
    Bardazzi F; Loi C; Sacchelli L; Di Altobrando A
    J Dermatolog Treat; 2020 Jun; 31(4):320-321. PubMed ID: 32248724
    [No Abstract]   [Full Text] [Related]  

  • 5. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
    Haberman R; Axelrad J; Chen A; Castillo R; Yan D; Izmirly P; Neimann A; Adhikari S; Hudesman D; Scher JU
    N Engl J Med; 2020 Jul; 383(1):85-88. PubMed ID: 32348641
    [No Abstract]   [Full Text] [Related]  

  • 6. Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits.
    Conforti C; Giuffrida R; Dianzani C; Di Meo N; Zalaudek I
    Dermatol Ther; 2020 Jul; 33(4):e13490. PubMed ID: 32358864
    [No Abstract]   [Full Text] [Related]  

  • 7. Should patients stop their biologic treatment during the COVID-19 pandemic.
    Bashyam AM; Feldman SR
    J Dermatolog Treat; 2020 Jun; 31(4):317-318. PubMed ID: 32191143
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply: "Biologics for psoriasis during COVID-19 outbreak".
    Di Lernia V
    J Am Acad Dermatol; 2020 Jun; 82(6):e217-e218. PubMed ID: 32283234
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 and immunomodulator/immunosuppressant use in dermatology.
    Price KN; Frew JW; Hsiao JL; Shi VY
    J Am Acad Dermatol; 2020 May; 82(5):e173-e175. PubMed ID: 32224277
    [No Abstract]   [Full Text] [Related]  

  • 10. Should biologics for psoriasis be interrupted in the era of COVID-19?
    Lebwohl M; Rivera-Oyola R; Murrell DF
    J Am Acad Dermatol; 2020 May; 82(5):1217-1218. PubMed ID: 32199889
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy.
    Filippi F; Loi C; Evangelista V; Bardazzi F
    Dermatol Ther; 2020 Jul; 33(4):e13805. PubMed ID: 32524715
    [No Abstract]   [Full Text] [Related]  

  • 12. Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto.
    Georgakopoulos JR; Yeung J
    J Cutan Med Surg; 2020; 24(4):424-425. PubMed ID: 32475151
    [No Abstract]   [Full Text] [Related]  

  • 13. A challenging case of psoriasis flare-up after COVID-19 infection.
    Nasiri S; Araghi F; Tabary M; Gheisari M; Mahboubi-Fooladi Z; Dadkhahfar S
    J Dermatolog Treat; 2020 Aug; 31(5):448-449. PubMed ID: 32363967
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.
    Valenti M; Facheris P; Pavia G; Gargiulo L; Borroni RG; Costanzo A; Narcisi A
    Dermatol Ther; 2020 Jul; 33(4):e13708. PubMed ID: 32474988
    [No Abstract]   [Full Text] [Related]  

  • 15. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
    Galluzzo M; Tofani L; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2020 Aug; 20(8):829-830. PubMed ID: 32510244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELSI Implications of Prioritizing Biological Therapies in Times of COVID-19.
    Druedahl LC; Lebret A; Minssen T
    J Law Med Ethics; 2020 Sep; 48(3):579-582. PubMed ID: 33021187
    [No Abstract]   [Full Text] [Related]  

  • 18. Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease.
    Bezzio C; Pellegrini L; Manes G; Arena I; Picascia D; Della Corte C; Devani M; Schettino M; Saibeni S
    Inflamm Bowel Dis; 2020 Sep; 26(10):e107-e109. PubMed ID: 32869831
    [No Abstract]   [Full Text] [Related]  

  • 19. Psoriasis-COVID 19 Infection: Treatment Options.
    Tampouratzi E; Kanni T; Katsantonis J; Douvali T
    Skinmed; 2020; 18(2):81-82. PubMed ID: 32501789
    [No Abstract]   [Full Text] [Related]  

  • 20. Biological treatment during COVID-19 outbreak.
    Sriwijitalai W; Wiwanitkit V
    J Dermatolog Treat; 2020 Jun; 31(4):324. PubMed ID: 32223353
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.